Aequus Pharmaceuticals Inc. Reports Revenue Results for the First Quarter Ended March 31, 2017; Provides Revenue Guidance for the Year 2017
Revenues are expected to continue to grow in the current year as these products continue to penetrate market share held by the branded equivalents and similar medications within the class, along with new prescription products that Aequus is currently negotiating for the Canadian market. Sales levels are expected to be inconsistent and unpredictable over the next twelve months as reimbursement activities and inventory stock-up occurs for each product.